title: Antioxidants in the prevention of atherosclerosis.
abstract: Four antioxidant treatment modalities against atherosclerosis and coronary heart disease are scrutinized: probucol, beta-carotene, alpha-tocopherol and anti-iron treatment. A pattern seems to have emerged in which some treatments look promising, but others are disappointing. Most published studies of antioxidation in atherosclerosis have been ad-hoc in that the primary endpoint of the study has not been a diagnosis related to atherosclerosis; this may be misleading. The most promising antioxidant seems to be alpha-tocopherol, supported by the results of the Cambridge Heart Antioxidant Study. Probucol has the drawback of decreasing high density lipoprotein concentration and is therefore unlikely to influence atheroma in people. beta-Carotene has been repeatedly shown to be ineffective against coronary heart disease. Anti-iron treatment has not yet been tested in animal models or in man. More has to be learned of the role of antioxidation in atherosclerosis before the effectiveness of this treatment modality can be established.
authors.affiliation: Department of Internal Medicine, University Hospital, Linköping, Sweden.
authors.forename: A G
authors.initials: AG
authors.lastname: Olsson
authors.forename: X M
authors.initials: XM
authors.lastname: Yuan
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000517:prevention & control*; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D011341:Probucol / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use; D019207:beta Carotene / Q000627:therapeutic use
chemical_list: D000924:Anticholesteremic Agents; D000975:Antioxidants; D007502:Iron Chelating Agents; D019207:beta Carotene; D014810:Vitamin E; D011341:Probucol